top of page
News
Search
20MED THERAPEUTICS PUBLISHES POSITIVE IN VIVO EFFICACY DATA OF A MRNA INFLUENZA VACCINE USING ITS PROPRIETARY POLYMERIC NANOPARTICLE TECHNOLOGY
Preclinical data underscores the potential to deliver a strong protective effect using Polymeric Nanoparticles (PNPs), an alternative to...
Apr 15, 2024
Come and meet us at BIO2024
Meet the 20Med Therapeutics team in San Diego during the BIO International Convention to discuss partnering opportunities around our PNP...
Apr 13, 2024
20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer
Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the...
Nov 29, 2023
bottom of page